
Zymeworks Inc.
ZYME
ZYME: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
moreShow ZYME Financials
Recent trades of ZYME by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ZYME's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on ZYME's company Twitter account
Number of mentions of ZYME in WallStreetBets Daily Discussion
Recent insights relating to ZYME
Recent picks made for ZYME stock on CNBC
ETFs with the largest estimated holdings in ZYME
Flights by private jets registered to ZYME